CompletedPhase 4

Study Evaluating the Efficacy and Safety of Remifentanil in a Rapid Sequence Induction for Fragile Subjects

France75 participantsStarted 2011-03-09

Plain-language summary

The primary objective is to determine whether, during a rapid sequence intubation by etomidate, and succinylcholine Sellick maneuver, the administration of remifentanil at 2 different dosages (0.5 and 1.0 microgram per kg body weight), reduces potentially dangerous reactional tachycardia.

Who can participate

Age range65 Years – 90 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients requiring rapid sequence intubation for whatever reason. This includes the following: a full stomach, obesity, diabetic gastroparesis, gastroesophageal reflux * Patient able to give informed consent, and sign the consent. Exclusion Criteria: * Contraindication for the use of any drugs used (regardless of the patient group): a history of serious side effects, allergic reaction * Morbid obesity (Body Mass Index \> 40) * Emergency situation with unstable hemodynamics, and stabilization is impossible before induction * Inclusion in another research project within the past 3 months * The patient is not insured or beneficiary of a health insurance plan (for the French centers) * Patient under guardianship of any kind * Patient unable to give informed consent * Refusal to sign the consent form

What they're measuring

Cardiac frequency (beats per minute)

Timeframe: 15 minutes

Trial details

NCT IDNCT01259648

SponsorCentre Hospitalier Universitaire de Nīmes

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2014-05-20

View on ClinicalTrials.gov More Tachycardia trials